ArticleJournal of Ayurveda and integrative medicine
Dose-dependent antidiabetic and multiorgan protective effects of Ziziphus abyssinica methanolic extract in streptozotocin-induced diabetic mice.
Article in Journal of Ayurveda and integrative medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetes mellitus (DM) is a global health challenge, with rising prevalence and significant economic burden, particularly in low- and middle-income countries. Current synthetic antidiabetic drugs, though effective, are associated with adverse effects, prompting interest in plant-based alternatives.
objectivesThis study evaluated the antidiabetic potential of Ziziphus abyssinica methanolic extract (ZAE) in streptozotocin (STZ)-induced diabetic mice.
methodsMale Swiss Albino mice were grouped into normal control, diabetic control, glibenclamide (5 mg/kg), and ZAE-treated (200, 400, 600 mg/kg) groups. Parameters were monitored for 28 days.
resultsZAE at 600 mg/kg normalized blood glucose (148.7 ± 11.0 mg/dL vs. normal control group 148.0 ± 3.0 mg/dL, ∗P∗ >0.05), achieving a 66 % reduction (∗P ∗ < 0.001) versus diabetic controls (437.2 ± 43.6 mg/dL). Body weight recovered fully (40.5 ± 1.9 g vs. 41.2 ± 1.2 g, ∗P ∗ >0.05), contrasting with a 25 % loss in diabetic controls (∗P∗ < 0.001). Lipid profiles improved, with HDL rising (61.8 ± 3.9 vs. 33 ± 2.4 mg/dL, ∗P∗ = 0.002) and LDL declining (37.5 ± 2.4 vs. 58.8 ± 3.7 mg/dL, ∗P∗ = 0.002). Liver (ALT, AST, ALP) and renal (creatinine, urea) markers normalized (∗P∗ < 0.05). Histopathology revealed β-cell preservation (∗P∗ < 0.01) and, specifically at the 600 mg/kg, a marked reduction in hepatic inflammation and renal protection.
conclusionThe 600 mg/kg ZAE demonstrated novel, dose-dependent efficacy not only in glycemic control but also in pancreatic β-cell preservation and multiorgan protection, showing significant benefits in renal and cardiac tissues where glibenclamide was ineffective. These findings suggest the traditional use of Ziziphus abyssinica and highlight the potential of 600 mg/kg regimen to provide concurrent glycemic control and multi-organ protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.